not tagged
CEL-SCI
['head and neck', '$cvm']
$cvm phase 3 data presented at #esmo22 neoadjuvant multikine achieved groundbreaking tumor response &amp; extended overall survival in locally advanced head and neck cancer 
Investor/trader focused primarily in the biopharma sector. 
Tweets are not investment advice and are not recommendations of any kind.